UK markets open in 3 hours 27 minutes

Pliant Therapeutics, Inc. (PLRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.90-0.62 (-4.95%)
At close: 04:00PM EDT
12.27 +0.37 (+3.11%)
After hours: 06:43PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close12.52
Open12.55
Bid11.84 x 100
Ask11.92 x 200
Day's range11.73 - 12.55
52-week range11.73 - 28.80
Volume368,605
Avg. volume363,770
Market cap755.191M
Beta (5Y monthly)1.12
PE ratio (TTM)N/A
EPS (TTM)-2.75
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est41.54
  • GlobeNewswire

    Pliant Therapeutics to Participate in Upcoming Investor Events

    SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following April investor events. 23rd Annual Needham Virtual Healthcare Conference Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, and Éric Lefebvre, M.D., Pliant’s Chief Medical Offi

  • GlobeNewswire

    Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

    Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company will present four scientific posters at the upcoming 2024 American Thoracic Society (ATS) International Conference, takin

  • GlobeNewswire

    Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

    Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast’s time to Phase 3 data Upsized Oxford Finance debt facility extends cash runway and funds accelerated development through 2026 SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment